Banner
Late-Breaking Analysis In Hypertension Shows That Antihypertensive Treatments Differ In Their Ability To Preserve Lives

STOCKHOLM, August 30, 2010 /PRNewswire/ -- According to the results of a late-breaking analysis...

Clinical Results For New Treatment Of Bacterial Vaginosis Infection

The Swedish company Laccure AB recently got CE marking as a Class IIa medical device product for...

88 Percent Of UK Doctors Believe Whiplash Claims Are Exaggerated

AXA, a UK car insurer, has surveyed UK doctors as part of its ongoing campaign to understand the...

On Facebook, Women Are More Plentiful But Men Are Better Ad Targets

Global digital marketing companies Resolution Media and Kenshoo Social published a new report today...

User picture.
Anna OhldenRSS Feed of this column.

Media Relations Executive, PR Newswire Europe... Read More »

Blogroll

LONDON, November 3 /PRNewswire/ --

- Financial Tsunami Sends Flood of Traffic to Business Finance Sites

- Facebook Displaces BBC Sites as the U.K.'s Fifth Largest Property

comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today released its September rankings of the largest and fastest-growing Internet properties and site categories in the U.K. based on data from the comScore World Metrix audience measurement service.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080115/COMSCORELOGO)

CALGARY, Canada, November 3 /PRNewswire/ -- Addax Petroleum Corporation (TSX: AXC and LSE: AXC) (Addax Petroleum or the Corporation) will announce its financial results for the quarter ended September 30, 2008 on Monday, November 10, 2008, and will discuss its financial results in a conference call on Monday, November 10, 2008 at 11:00 a.m. Eastern Time/4:00 p.m. London, U.K. time. Mr. Jean Claude Gandur, President and Chief Executive Officer, Mr. James Pearce, Chief Operating Officer, and Mr. Michael Ebsary, Chief Financial Officer, will discuss the Corporation's most recent financial and operating results.

HELSINKI, November 3 /PRNewswire/ -- Biohit is extending its range of diagnostic tests for gastrointestinal diseases with ColonView Hb and Hb/Hp quick tests, which are intended to aid early diagnosis and prevention of colorectal cancer. ColonView testing can be used for simple and cost-effective identification of patients with fecal occult blood, which is a well-known marker for colorectal cancer and pre-cancerous large adenomas. ColonView testing can also give information on possible other disease of the gastrointestinal tract that is associated with bleeding.

ColonView Hb test detects human hemoglobin (Hb) from red blood cells, and ColonView Hb/Hp test detects hemoglobin/haptoglobin complex (Hb/Hp).

SYDNEY, November 3 /PRNewswire/ -- Australia's 2002 Wimbledon champion Lleyton Hewitt is conducting a month long fund-raising charity auction during November on website http://www.eswap.com with proceeds going to Cure Our Kids, which helps kids with cancer and their families.

LONDON, November 3 /PRNewswire/ -- AboveNet Communications UK Ltd., a leading provider of fibre optic connectivity solutions for business and carriers and a subsidiary of AboveNet Inc., has been named a Gold Award recipient in the City of London's annual Considerate Contractor Scheme (CCS) for the second year in a row. The awards ceremony was held on Friday 31st October 2008, at Plaisterers Hall in London.

CLEVELAND, Ohio and LOD, Israel, November 3 /PRNewswire/ -- Simbionix USA Corporation (Simbionix), a developer of medical simulators and hands-on curriculum for training medical professionals, today announced that William E. Lewandowski will join the company as the US Marketing Director on November 10th, 2008. Gary Zamler, Simbionix CEO stated, Over the past two consecutive years, Simbionix has enjoyed double digit revenue growth in both our International and Domestic markets. We are particularly pleased to have someone of Bill's caliber join our expanding US organization to increase the momentum as we rollout new and exciting products such as 'PROcedure Rehearsal Studio' the Simulation Industry's first patient specific technology.